qniv nanoparticle vaccine2
Vaccineexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 8, 2021 (NCT04961541)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06482359 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2024 | Novavax |
| NCT06291857 | Phase 3 | Oct 21, 2024 | Novavax |
| NCT05519839 | Phase 2 | Jan 16, 2023 | Novavax |
| NCT04961541 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2021 | Novavax |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novavax | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1